Spur Therapeutics

On October 23, we will present new data from our GALILEO-1 study of FLT201 in adults with Gaucher disease. These data will be highlighted in an oral presentation during a session on AAV gene therapy advances at the 31st Annual ESGCT Congress in Rome. If you're going to be at ESGCT, be sure to see our head of clinical development Francesca Ferrante discuss FLT201 on Wednesday the 23rd - the session starts at 8:30am CEST. Read our latest announcement for more details: https://bit.ly/3ZJz5y2

October 1 is International Gaucher Day and the start of Gaucher Disease Awareness Month, an opportunity to recognize the impact this condition has on thousands of people worldwide. Many Gaucher patients on current therapies still experience symptoms like enlarged organs, fatigue and bone pain. Continued research into new treatment options for Gaucher disease is needed to address these debilitating symptoms.

Did you know that #adrenomyeloneuropathy (AMN) is inherited through the X chromosome? Because of this, most affected individuals are male, although anyone with an X-linked mutation to the ABCD1 gene can experience symptoms. The symptoms of AMN are wide-ranging and can affect a number of body systems. The National Institutes of Health have created a comprehensive informational page highlighting patient demographics, frequency of symptoms, and resources for patients and caregivers. This #LeukodystrophyAwarenessMonth, we encourage our followers to learn more about this devastating illness: https://bit.ly/4dCrBAw

In honor of #HispanicHeritageMonth, we’re recognizing influential Hispanic scientists who have made essential contributions to our field. Dr. Lydia Villa-Komaroff is a pioneer in recombinant DNA research whose work has informed the way researchers study many diseases – one of her most impactful discoveries was the first direct proof of how amyloid beta causes neurodegeneration, opening avenues for the potential treatment of devastating conditions like Alzheimer's disease. Throughout her career she has been a committed advocate for diversity in STEM. 

Yesterday, we held a hybrid town hall at our headquarters in Stevenage. As we prepare for several exciting milestones in the coming months, our team gathered to celebrate the year’s successes thus far and reaffirm our plans to tackle Spur’s priorities through the rest of 2024 – followed by a fun chocolate tasting event organized by our Culture Club!   With our ongoing clinical trials in #GaucherDisease and #Adrenomyeloneuropathy, as well as multiple preclinical research programs, we remain dedicated to spurring gene therapy #TowardMore.

We recently had the pleasure of welcoming Jeff Harmon, an executive coach and the founder of the nonprofit organization “My Impossible,” to share his experience living with #adrenomyeloneuropathy (AMN) and his belief in confronting fears and living fully. Following his life-changing AMN diagnosis, which placed him in a wheelchair in 2017, Jeff embraced living fearlessly – our team was inspired by his story and his commitment to service, community, and helping motivate others. As Jeff prepares for his latest adventure (climbing Mount Kilimanjaro in 2025!), the Spur team is working to identify and conquer our own challenges previously deemed impossible. Thank you, Jeff, for your impactful words and for taking the time during #Leukodystrophy Awareness Month to share your story! 

We recently asked the members of our team to share how they’re working #TowardMore at Spur. Take a look at the responses – our colleagues are motivated by a variety of opportunities, but they are all guided by Spur’s mission to redefine gene therapy. Visit our website to learn about Spur’s work Toward More: https://bit.ly/4chv8mA

Are you in Nashville for the BioCentury Inc. Grand Rounds event? Be sure to attend the AAV gene therapy panel on Tuesday, September 10, at 1:30pm CT – Spur CSO Henning Stennicke, PhD, will be a featured panelist discussing opportunities for continued progress and innovation in this space. In addition, Spur CEO Michael Parini will give a corporate presentation Tuesday at 11:30am CT to share the latest updates on our work, and we will have a poster covering our Parkinson’s disease program available later that day from 5:30 – 7:00pm CT. We’re pleased to be among the leading voices in gene therapy sharing our perspectives at this event. Learn more: https://lnkd.in/ehixbvAx

September is #Leukodystrophy Awareness Month – this group of rare, genetic diseases includes #adrenomyeloneuropathy (AMN), which is caused by a mutation of the ABCD1 gene. AMN is characterized by devastating symptoms including mobility loss, incontinence, debilitating pain, and sexual dysfunction. There are currently no treatment options to slow or alter the progression of AMN, and there is a tremendous unmet need for new therapies to address the root cause of this disease.

We are participating in the BioCentury Inc. Grand Rounds in Nashville from September 9-11 – we look forward to joining industry leaders to discuss upcoming breakthroughs in biopharma R&D. We will share a poster highlighting our Parkinson’s disease program, and our CEO Michael Parini will give a corporate presentation on September 10 at 11:30am CT. We hope to see you there! https://lnkd.in/ehixbvAx